The cost effect of newer medication adoption in an older Medicaid cohort

Journal of the American Geriatrics Society

Volumn 53, Issue 8, 2005, Pages 1366-1373

  Shireman, Theresa I ^a,b   Rigler, Sally K ^b   Jachna, Carolyn M ^b   Griebling, Tomas L ^b   Eng, Marty L ^a,b  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Elderly; Medicaid; Prescription drug costs; Prescription drug utilization; Trends

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; NEUROLEPTIC AGENT; OPIATE; DRUG;

ADOPTIVE TRANSFER; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MARKETING; DRUG UTILIZATION; FEMALE; GERIATRIC CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; PRESCRIPTION; RETROSPECTIVE STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ECONOMICS; INSTITUTIONALIZATION; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

AGED; FEMALE; HUMANS; INSTITUTIONALIZATION; KANSAS; MALE; MEDICAID; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES;

EID: 25144464945     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2005.53419.x     Document Type: Article

References (24)

1. Crowley JS, Ashner D, Elam L. Medicaid outpatient Prescription Drug Benefits: Findings from a National Survey. 2003, Kaiser Commission on Medicaid and the Uninsured. Washington, DC: Kaiser Family Foundation, 2003.
2. President's Task Force of Medicaid Reform, Final Report to the 2003 Kansas Legislature. Topeka, KS: 2003.
3. Pharmacy Benefit Report. Facts and Figures, 1999 Edition, East Hanover, NJ: Novartis Pharmaceuticals, 1999.
4. How the Medicaid Rebate on Prescription Drugs Affects Pricing in the Pharmaceutical Industry, CBO Papers, Washington, DC: Congressional Budget Office, 1996.
5. Neumann PJ, Sandberg EA, Bell CM et al. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff 2000;19:92-109.
6. Als-Nielsen B, Chen W, Gluud C et al. Association of funding and conclusions in randomized drug trials: A reflection of treatment effect or adverse events? JAMA 2003;290:921-928.
7. Spiegel FMR, Targownik L, Dulai FS et al. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003;138:795-806.
8. Jacoby A, Smith M, Eccles M. A qualitative study to explore influences on general practitioners' decisions to prescribe new drugs. Br J Gen Pract 2001;53:120-125.
9. Zara C, Torralba M, Sotoca JM et al. The impact of new drug introduction on drug expenditure in primary health care in Catalunya, Spain. Ann Pharmacother 2005;39:177-182.
10. Changing Patterns of Pharmaceutical Innovation. Washington, DC: National Institute for Health Care Management Research and Educational Foundation, 2002.
11. American Geriatrics Society and American Association for Geriatric Psychiatry. Consensus statement on improving the quality of mental health care in U.S. nursing homes: Management of depression and behavioral symptoms associated with dementia. J Am Geriatr Soc 2003;51:2187-2198.
12. Smalley WE, Griffin MR, Fought RL et al. Effect of a prior-authorization requirement on the use of nonsteroidal anti-inflammatory drugs by Medicaid patients. N Engl J Med 1995;332:1612-1617.
13. Shaw E, Stacy J, Arledge MD et al. Pharmacoeconomic modeling of prior-authorization interventions for COX-2 specific inhibitors in a 3-tier copay plan. J Manag Care Pharm 2003;9:327-334.
14. Adams AS, Soumerai SB, Ross-Degnan D. Use of antihypertensive drugs by Medicare enrollees: Does type of drug coverage matter? Health Aff 2001;20:276-286.
15. Federman AD, Adams AS, Ross-Degnan D et al. Supplemental insurance and use of effective cardiovascular drugs among elderly Medicare beneficiaries with coronary heart disease. JAMA 2001;286:1732-1739.
16. Goldman DP, Joyce GF, Escarce JJ et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA 2004;291:2344-2350.
17. Heisler M, Langa KM, Eby EL et al. The health effects of restricting prescription medication use because of cost. Med Care 2004;42:626-634.
18. Kennedy J, Coyne J, Sclar D. Drug affordability and prescription noncompliance in the United States: 1997-2002. Clin Ther 2004;26:607-614.
19. Mojtabai R, Olfson M. Medication costs, adherence, and health outcomes among Medicare beneficiaries. Health Aff 2003;22:220-229.
20. Steinman MA, Sands LP, Covinsky KE. Self-restriction of medications due to cost in seniors without prescription coverage. J Gen Intern Med 2001;16:793-799.
21. Tseng CW, Brook RH, Keeler E et al. Cost-lowering strategies used by Medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA 2004;292:952-960.
22. Moore WJ. Medicaid drug utilization review: A critical appraisal. Med Care Rev 1994;51:3-37.
23. Fisher MA, Avorn J. Economic consequences of underuse of generic drugs: Evidence from Medicaid and implications for prescription drug benefit plans. Health Serv Res 2003;38:1051-1063.
24. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff 2004;23:135-146.